Mersana Therapeutics, Inc.
MRSNDelisted Jan 6, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001442836
Mersana Therapeutics, Inc. was delisted on Jan 6, 2026; its insiders filed their last Form 4 on Jan 6, 2026; 51 institutions reported holding it in 13F filings for Q4 2025, worth $64.8M in total; no superinvestor held it.
13F holders, Q4 2021
Institutional positions in Mersana Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 122
- +14 vs. Q3 2021
- Shares held
- 70.2M
- +1.51M (+2.2%) vs. Q3 2021
- Total value
- $436.6M
- −$211.1M (−32.6%) vs. Q3 2021
- New holders
- 30
- 45 more added
- Sold out
- 16
- 24 more reduced
2 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MRSN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 1 | $87 |
| Q4 2025 | 51 | $64.8M |
| Q3 2025 | 49 | $24.7M |
| Q2 2025 | 85 | $22.9M |
| Q1 2025 | 111 | $30.2M |
| Q4 2024 | 132 | $149.2M |
| Q3 2024 | 116 | $219.4M |
| Q2 2024 | 122 | $229.6M |
| Q1 2024 | 125 | $526.3M |
| Q4 2023 | 106 | $263.0M |
| Q3 2023 | 128 | $144.4M |
| Q2 2023 | 147 | $370.2M |
| Q1 2023 | 158 | $437.2M |
| Q4 2022 | 152 | $592.8M |
| Q3 2022 | 152 | $623.4M |
| Q2 2022 | 126 | $408.0M |
| Q1 2022 | 128 | $322.7M |
| Q4 2021 | 122 | $436.6M |
| Q3 2021 | 110 | $648.3M |
| Q2 2021 | 131 | $957.8M |
| Q1 2021 | 132 | $1.14B |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Mersana Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Northern Trust Corp | 747,876 | $4.65M | 0.00% | +50,863+7.3% | Added |
| Rho Capital Partners Inc | 796,458 | $4.95M | 3.22% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 818,100 | $5.09M | 0.02% | +818,100 | New |
| Two Sigma Investments, LP | 877,752 | $5.46M | 0.01% | +529,507+152.1% | Added |
| Two Sigma Advisers, LP | 1,050,200 | $6.53M | 0.02% | +420,200+66.7% | Added |
| CIBC Asset Management Inc | 1,055,994 | $6.57M | 0.02% | −2,804−0.3% | Reduced |
| Assenagon Asset Management S.A. | 1,073,748 | $6.68M | 0.02% | +169,882+18.8% | Added |
| Geode Capital Management, LLC | 1,137,001 | $7.07M | 0.00% | +72,666+6.8% | Added |
| Artal Group S.A. | 1,200,000 | $7.46M | 0.22% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 1,209,612 | $7.52M | 0.00% | +64,243+5.6% | Added |
| Morgan Stanley | 1,228,607 | $7.64M | 0.00% | +560,718+84.0% | Added |
| Candriam Luxembourg S.C.A. | 2,022,895 | $12.6M | 0.08% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 2,888,847 | $18.0M | 0.23% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 3,248,950 | $20.2M | 0.47% | +228,248+7.6% | Added |
| Vanguard Group Inc | 3,607,431 | $22.4M | 0.00% | −74,163−2.0% | Reduced |
| Bellevue Group AG | 4,164,000 | $25.9M | 0.27% | −97,000−2.3% | Reduced |
| State Street Corp | 4,220,557 | $26.3M | 0.00% | +130,361+3.2% | Added |
| Sarissa Capital Management LP | 4,299,297 | $26.7M | 2.31% | 00.0% | Unchanged |
| Wellington Management Group LLP | 5,017,078 | $31.2M | 0.00% | −990,297−16.5% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 5,385,667 | $33.5M | 2.66% | +1,690,000+45.7% | Added |
| Avoro Capital Advisors LLC | 6,800,000 | $42.3M | 0.72% | 00.0% | Unchanged |
| BlackRock Inc. | 7,479,229 | $46.5M | 0.00% | −1,328,099−15.1% | Reduced |
| Pictet Asset Management SA | 0 | $0 | 0.00% | −2,237,868−100.0% | Sold out |
| Alkeon Capital Management LLC | 0 | $0 | 0.00% | −1,799,838−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −384,736−100.0% | Sold out |
| First Manhattan Co | 0 | $0 | 0.00% | −218,070−100.0% | Sold out |
| AlphaCentric Advisors LLC | 0 | $0 | 0.00% | −65,500−100.0% | Sold out |
| TD Asset Management Inc | 0 | $0 | 0.00% | −45,057−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −22,764−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −21,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −18,777−100.0% | Sold out |
| Allstate Corp | 0 | $0 | 0.00% | −13,667−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −12,330−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −11,779−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −1,640−100.0% | Sold out |
| O'Shaughnessy Asset Management, LLC | 0 | $0 | 0.00% | −651−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −173−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |
| First Mercantile Trust Co | – | – | – | – | Not filed |